Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial.
Acute respiratory failure
Artificial
COVID-19
Intensive care units
Nicotine
Nicotinic receptor
Randomized trial
Ventilation
Journal
Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
27
02
2022
accepted:
27
04
2022
pubmed:
9
6
2022
medline:
14
7
2022
entrez:
8
6
2022
Statut:
ppublish
Résumé
Epidemiologic studies have documented lower rates of active smokers compared to former or non-smokers in symptomatic patients affected by coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of nicotine administered by a transdermal patch in critically ill patients with COVID-19 pneumonia. In this multicentre, double-blind, placebo-controlled trial conducted in 18 intensive care units in France, we randomly assigned adult patients (non-smokers, non-vapers or who had quit smoking/vaping for at least 12 months) with proven COVID-19 pneumonia receiving invasive mechanical ventilation for up to 72 h to receive transdermal patches containing either nicotine at a daily dose of 14 mg or placebo until 48 h following successful weaning from mechanical ventilation or for a maximum of 30 days, followed by 3-week dose tapering by 3.5 mg per week. Randomization was stratified by centre, non- or former smoker status and Sequential Organ Function Assessment score (< or ≥ 7). The primary outcome was day-28 mortality. Main prespecified secondary outcomes included 60-day mortality, time to successful extubation, days alive and free from mechanical ventilation, renal replacement therapy, vasopressor support or organ failure at day 28. Between November 6th 2020, and April 2nd 2021, 220 patients were randomized from 18 active recruiting centers. After excluding 2 patients who withdrew consent, 218 patients (152 [70%] men) were included in the analysis: 106 patients to the nicotine group and 112 to the placebo group. Day-28 mortality did not differ between the two groups (30 [28%] of 106 patients in the nicotine group vs 31 [28%] of 112 patients in the placebo group; odds ratio 1.03 [95% confidence interval, CI 0.57-1.87]; p = 0.46). The median number of day-28 ventilator-free days was 0 (IQR 0-14) in the nicotine group and 0 (0-13) in the placebo group (with a difference estimate between the medians of 0 [95% CI -3-7]). Adverse events likely related to nicotine were rare (3%) and similar between the two groups. In patients having developed severe COVID-19 pneumonia requiring invasive mechanical ventilation, transdermal nicotine did not significantly reduce day-28 mortality. There is no indication to use nicotine in this situation.
Identifiants
pubmed: 35676335
doi: 10.1007/s00134-022-06721-1
pii: 10.1007/s00134-022-06721-1
pmc: PMC9177407
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Banques de données
ClinicalTrials.gov
['NCT04598594']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
876-887Investigateurs
Jessica Palmyre
(J)
Linda Gimeno
(L)
Assitan Kone
(A)
Cedric Vialette
(C)
Ouramdane Slimi
(O)
Juliette Chommeloux
(J)
Lucie Lefevre
(L)
Matthieu Schmidt
(M)
Guillaume Hekimian
(G)
Charles-Edouard Luyt
(CE)
Laure Stiel
(L)
Anne-Florence Dureau
(AF)
Kuteifan Khaldoun
(K)
Hanna Eid
(H)
Matthieu Baldacini
(M)
Cecile Zyberfajn
(C)
Julien Manson
(J)
Nathanael Charrier
(N)
Angelique Balabanian
(A)
Damien Contou
(D)
Olivier Pajot
(O)
Megan Fraisse
(M)
Paul Desaint
(P)
Florence Sarfati
(F)
Muriel Fartoukh
(M)
Guillaume Voirot
(G)
Alexandre Elabbabi
(A)
Michel Djibre
(M)
Cyrielle Desnos
(C)
Pierre Garcon
(P)
Ly van Vong
(L)
Andrea Issad
(A)
Bertrand Pillot
(B)
Delphine Reither
(D)
Patrick Rouge
(P)
Pascale Foliot
(P)
Lynda Bendjamar
(L)
Valentin Pointurier
(V)
Hadrien Winiszewski
(H)
Gilles Capellier
(G)
Jean-Christophe Navellou
(JC)
Romain Tapponnier
(R)
Emilie Panicucci
(E)
Lucas Morand
(L)
Jean Dellamonica
(J)
Clement Saccheri
(C)
Nicolas Weiss
(N)
Clemence Marois
(C)
Loic Le Guennec
(L)
Benjamin Rohaut
(B)
Luis Ensenat
(L)
Cecilia Billiou
(C)
Maria Aroca
(M)
Marie Baron
(M)
Alexandre Demoule
(A)
Alexandra Beurton
(A)
Come Bureau
(C)
Maxens Decavele
(M)
Martin Dres
(M)
Frederique Bayle
(F)
Quoc Viet Le
(QV)
Lionel Liron
(L)
Jean-Baptiste Putegnat
(JB)
Francois Salord
(F)
Pascal Andreu
(P)
Hakim Slimani
(H)
Baptiste Roudeau
(B)
Marie Labruyere
(M)
Marine Jacquier
(M)
Nadia Anguel
(N)
Soufia Ayed
(S)
Edgard Durand
(E)
Laurent Guerin
(L)
Christopher Lai
(C)
Jerome Aboab
(J)
Sophie Alviset
(S)
Laurent Laine
(L)
Mathilde Azzi
(M)
Tazime Issoufaly
(T)
Laurent Tric
(L)
Lyes Knani
(L)
Chahrazad Bey Boumezrag
(CB)
Nicolas Viault
(N)
Francois Barbier
(F)
Thierry Boulain
(T)
Toufik Kamel
(T)
Mai-Anh Nay
(MA)
Sophie Tollec
(S)
An Hung Nguyen
(AH)
Informations de copyright
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Centers for Disease Control and Prevention: SARS-CoV-2 Variant Classifications and Definitions https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Concern ; Last accessed, January 1st, 2022
Del Rio C, Omer SB, Malani PN (2021) Winter of omicron-the evolving COVID-19 pandemic. JAMA 2:2
Miyara M, Tubach F, Pourcher V et al (2022) Low rate of daily smokers in patients with symptomatic COVID-19: a monocentric self-report of smoking habit study. Front Med. https://doi.org/10.3389/fmed.2021.668995
doi: 10.3389/fmed.2021.668995
Farsalinos K, Barbouni A, Niaura R (2020) Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med 15:845–852
pubmed: 32385628
pmcid: 7210099
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720
pubmed: 32109013
Simons D, Shahab L, Brown J et al (2021) The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction (Abingdon, England) 116:1319–1368
Fontanet A, Tondeur L, Grant R, et al. (2021) SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 26
Paleiron N, Mayet A, Marbac V et al (2021) Impact of tobacco smoking on the risk of COVID-19: a large scale retrospective cohort study. Nicotine Tobacco Res 23:1398–1404
González-Rubio J, Navarro-López C, López-Nájera E et al (2020) A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int J Environ Res Public Health 17:2
Reddy RK, Charles WN, Sklavounos A et al (2021) The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol 93:1045–1056
pubmed: 32749705
Lowe KE, Zein J, Hatipoglu U et al (2021) Association of smoking and cumulative pack-year exposure with COVID-19 outcomes in the cleveland clinic COVID-19 registry. JAMA Intern Med 181:709–711
pubmed: 33492361
pmcid: 7835916
Yan R, Zhang Y, Li Y et al (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448
pubmed: 32132184
pmcid: 7164635
Oakes JM, Fuchs RM, Gardner JD et al (2018) Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 315:R895-r906
pubmed: 30088946
pmcid: 6295500
Changeux JP, Amoura Z, Rey FA et al (2020) A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. CR Biol 343:33–39
Tizabi Y, Getachew B, Copeland RL et al (2020) Nicotine and the nicotinic cholinergic system in COVID-19. FEBS J 287:3656–3663
pubmed: 32790936
Dautzenberg B, Levi A, Adler M et al (2021) Transdermal nicotine in non-smokers: a systematic review to design COVID-19 clinical trials. Respir Med Res 80:100844
pubmed: 34153704
pmcid: 8183099
Wang H, Yu M, Ochani M et al (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384–388
pubmed: 12508119
Fujii T, Mashimo M, Moriwaki Y et al (2017) Expression and function of the cholinergic system in immune cells. Front Immunol 8:1085
pubmed: 28932225
pmcid: 5592202
Farsalinos K, Eliopoulos E, Leonidas DD et al (2020) Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications. Int J Mol Sci 21:2
Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E et al (2020) Cytokine release syndrome (CRS) and nicotine in COVID-19 patients: trying to calm the storm. Front Immunol 11:1359
pubmed: 32595653
pmcid: 7300218
Gomes JP, Watad A, Shoenfeld Y (2018) Nicotine and autoimmunity: The lotus’ flower in tobacco. Pharmacol Res 128:101–109
pubmed: 29051105
Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963
pubmed: 8254858
Lameire N, Levin A, Kellum JA et al (2021) Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) Consensus Conference. Kidney Int 2:2
Base documentaire de l'APHP sur la COVID-19: http://covid-documentation.aphp.fr/ ; Last accessed, January 1st 2022
IDSA Guidelines on the Treatment and Management of Patients with COVID-19: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ ; Last accessed, January 11st 2022
Beitler JR, Sarge T, Banner-Goodspeed VM et al (2019) Effect of titrating positive end-expiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 321:846–857
pubmed: 30776290
pmcid: 6439595
(2021) COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 47: 60–73
Grasselli G, Zangrillo A, Zanella A et al (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323:1574–1581
pubmed: 32250385
pmcid: 7136855
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
Buyse M (2010) Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. Stat Med 29:3245–3257
pubmed: 21170918
Kamiński M, Muth A, Bogdański P (2020) Smoking, vaping, and tobacco industry during COVID-19 pandemic: twitter data analysis. Cyberpsychol Behav Soc Netw 23:811–817
pubmed: 32757951
Kavuluru R, Noh J, Rose SW (2021) Twitter discourse on nicotine as potential prophylactic or therapeutic for COVID-19. Int J Drug Policy 99:103470
pubmed: 34607223
pmcid: 8450069
Ghosh A, Girish V, Yuan ML et al (2021) Combustible and electronic cigarette exposures increase ACE2 activity and SARS-CoV-2 spike binding. Am J Respir Crit Care Med 2:2
Masso-Silva JA, Moshensky A, Shin J et al (2021) Chronic E-cigarette aerosol inhalation alters the immune state of the lungs and increases ACE2 expression, raising concern for altered response and susceptibility to SARS-CoV-2. Front Physiol 12:649604
pubmed: 34122126
pmcid: 8194307
Tomchaney M, Contoli M, Mayo J et al (2021) Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease. BMC Pulm Med 21:275
pubmed: 34425811
pmcid: 8381712
Hopkinson NS, Rossi N, El-Sayed Moustafa J et al (2021) Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax 76:714–722
pubmed: 33402392
Ioannou GN, Locke E, Green P et al (2020) Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection. JAMA Netw Open 3:e2022310
pubmed: 32965502
pmcid: 7512055
Razjouyan J, Helmer DA, Lynch KE et al (2021) Smoking status and factors associated with COVID-19 in-hospital mortality among US veterans. Nicotine Tobacco Res 2:2
Mazeraud A, Jamme M, Mancusi RL, et al., (2021) Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med
Karagiannidis C, Mostert C, Hentschker C et al (2020) Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 8:853–862
pubmed: 32735842
pmcid: 7386882
Patel BV, Haar S, Handslip R et al (2021) Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom. Intensive Care Med 47:549–565
pubmed: 33974106
pmcid: 8111053
Schmidt M, Hajage D, Lebreton G et al (2020) Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med 8:1121–1131
pubmed: 32798468
pmcid: 7426089
Yang X, Yu Y, Xu J et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8:475–481
pubmed: 32105632
pmcid: 7102538
de Jong B, Schuppers AS, Kruisdijk-Gerritsen A et al (2018) The safety and efficacy of nicotine replacement therapy in the intensive care unit: a randomised controlled pilot study. Ann Intensive Care 8:70
pubmed: 29881956
pmcid: 5991106
Gottlieb RL, Vaca CE, Paredes R et al (2021) Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2:2
Gillies MA, McKenzie CA, Whiteley C et al (2012) Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study. Intensive Care Med 38:1683–1688
pubmed: 22618096
Angus DC, Derde L, Al-Beidh F et al (2020) Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 324:1317–1329
pubmed: 32876697
pmcid: 7489418
Horby P, Lim WS, Emberson JR et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384:693–704
pubmed: 32678530